Pdt Partners, LLC Compugen LTD Transaction History

Pdt Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.57 - $3.33 $279,984 - $593,852	-178,334 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.76 - $4.64 $115,227 - $193,715	-41,749 Reduced 18.97%	178,334 $574,000
Q4 2021 Feb 14, 2022	BUY	$4.09 - $7.16 $322,631 - $564,802	78,883 Added 55.87%	220,083 $946,000
Q2 2021 Aug 16, 2021	SELL	$6.87 - $9.16 $779,236 - $1.04 Million	-113,426 Reduced 44.55%	141,200 $1.17 Million
Q1 2021 May 17, 2021	SELL	$7.67 - $13.77 $145,952 - $262,029	-19,029 Reduced 6.95%	254,626 $2.19 Million
Q4 2020 Feb 16, 2021	BUY	$12.07 - $17.95 $169,643 - $252,287	14,055 Added 5.41%	273,655 $3.31 Million
Q3 2020 Nov 16, 2020	BUY	$14.16 - $19.45 $1.84 Million - $2.53 Million	130,144 Added 100.53%	259,600 $4.22 Million
Q2 2020 Aug 14, 2020	BUY	$6.97 - $17.12 $675,086 - $1.66 Million	96,856 Added 297.1%	129,456 $1.94 Million
Q1 2020 May 15, 2020	BUY	$5.79 - $11.83 $80,481 - $164,437	13,900 Added 74.33%	32,600 $237,000
Q4 2019 Feb 14, 2020	BUY	$3.9 - $6.16 $72,930 - $115,192	18,700 New	18,700 $111,000

13.1M

79.2K

12.7K

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $131M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.